Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 13/20 | 0.67 |
| ▸ | AXL | P30530 | 6/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16631046 | 0.85 | MAPK1 (0.67) | MAPK1 | |
| SCHEMBL16631146 | 0.84 | MAPK1 (0.78) | MAPK1 | |
| SCHEMBL21107158 | 0.83 | MAPK1 (0.66) | MAPK1 | |
| SCHEMBL16631205 | 0.83 | MAPK1 (0.74) | MAPK1AXLPIM1 | |
| SCHEMBL16631042 | 0.83 | MAPK1 (0.74) | MAPK1 | |
| SCHEMBL16631192 | 0.82 | MAPK1 (0.72) | MAPK1 | |
| SCHEMBL16620654 | 0.81 | MAPK1 (0.83) | MAPK1 | |
| SCHEMBL19223415 | 0.80 | MAPK1 (1.00) | MAPK1CYP3A4 | |
| SCHEMBL16620235 | 0.80 | MAPK1 (1.00) | MAPK1CYP3A4 | |
| SCHEMBL16224926 | 0.80 | MAPK1 (1.00) | MAPK1AXLPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020046966-A1 | TREATMENT OF ADENOCARCINOMAS WITH MAPK PATHWAY INHIBITORS | KURA ONCOLOGY, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190192517-A1 | TREATMENT OF SQUAMOUS CELL CARCINOMAS WITH INHIBITORS OF ERK | KURA ONCOLOGY, INC. | 2019-06-27 | — | — | US | disclosed |
| US-10301317-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-9951078-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170226110-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9624228-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160237091-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2016-08-18 | — | — | US | disclosed |
| WO-2015051341-A1 | INHIBITORS OF ERK AND METHODS OF USE | ARAXES PHARMA LLC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301317-B2 | Inhibitors of ERK and methods of use | MAP3K1, MAP3K2, MAP3K6 | MAPK1 12/4885AXL 807/4885CYP3A4 4421/4885 |
| US-20170226110-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | MAPK1 12/4885AXL 807/4885CYP3A4 4421/4885 |
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | MAPK1 12/4885AXL 807/4885CYP3A4 4421/4885 |
| US-20160237091-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | MAPK1 12/4885AXL 807/4885CYP3A4 4421/4885 |
| US-20190192517-A1 | TREATMENT OF SQUAMOUS CELL CARCINOMAS WITH INHIBITORS OF ERK | HRAS, TP53, MAP3K2 | MAPK1 51/4885AXL 2410/4885CYP3A4 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.